Prudential plc stock slips as $1.2bn buyback kicks off; investors eye March results

Prudential plc stock slips as $1.2bn buyback kicks off; investors eye March results

London, Jan 7, 2026, 09:26 GMT — Regular session

Prudential plc shares slipped in early London trade on Wednesday, pulling back from a fresh 52-week high after the insurer launched a new share buyback. Prudential was down 1.4% at 1,179 pence, after opening at 1,205 and hitting an intraday low of 1,176; the stock touched 1,213 pence on Tuesday.

Prudential said on Tuesday it would repurchase up to $1.2 billion of ordinary shares, a move that reduces the number of shares in issue and returns cash to shareholders. The programme, scheduled to run until no later than Dec. 18, 2026, includes $500 million of recurring capital returns and $700 million tied to net proceeds from the ICICI Prudential Asset Management IPO, with the remainder earmarked for 2027; the group has said it expects to return more than $5 billion over 2024-2027 before that further IPO-related return. Chief Executive Anil Wadhwani said: “I am pleased with the progress we are making in executing our strategy.” SEC

An announcement on Wednesday showed Prudential has already begun buying shares under the programme, purchasing 316,603 shares on Jan. 6 at an average price of about 1,199.48 pence, with the company set to cancel the shares. Prudential said the buyback cut its issued share capital to about 2.548 billion shares.

The new buyback follows the flotation of Prudential’s Indian asset management joint venture. Prudential sold a 4.5% stake in ICICI Prudential Asset Management ahead of the IPO for about $545 million, and said proceeds from the private placement and the IPO would be returned to shareholders, subject to regulatory and shareholder approvals.

The buyback announcement helped lift the stock in the previous session, after a run that put Prudential near its highs for the year. “Prudential is staging gains thanks to the launch of a $1.2 billion share buyback programme,” said Victoria Scholar, head of investment at interactive investor, in a market note on Tuesday. The Guardian

But the company has flagged limits on how much support the programme can offer in a choppy market. Prudential said there was “no guarantee” the buyback would be completed in full, and that the pace and timing would depend on market conditions and execution considerations. Investegate

Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech. His coverage ranges from stocks and technology to economic developments across global markets. He worked in investment research and market analysis before becoming a financial journalist and is a graduate of the Lahore University of Management Sciences (LUMS).

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 Strong buy

Alphabet

Alphabet Inc. (NASDAQ:GOOGL) 91/100 • ★★★★½
#2 Strong buy

Amazon

Amazon (NASDAQ:AMZN) 89/100 • ★★★★½
#3 Buy

Microsoft

Microsoft (NASDAQ:MSFT) 87/100 • ★★★★
#4 Buy

Visa

Visa (NYSE:V) 84/100 • ★★★★
#5 Accumulate on pullback

Exxon Mobil

ExxonMobil (NYSE:XOM) 80/100 • ★★★★
View full portfolio
Editorial model selection. Not personalised advice.
MARKET CALENDAR

Key Events Today

The catalysts most likely to move markets.

#1

FOMC minutes

A potential catalyst for Treasury yields, the dollar, and rate-sensitive stocks as investors reconsider the July pause and the three dissenting votes.

#2

20-year Treasury auction

A weak or strong reception can swiftly impact long-term yields, stock valuations, and expectations for mortgage rates.

#3

Retail earnings cluster

Target, Lowe’s, and TJX offer insight into discretionary spending trends, value-focused consumer behavior, and housing-related expenditures.

View full calendar
Times and estimates may change. Verify before trading.
BP stock slips in premarket as oil dips on Venezuela turmoil — what investors watch next
Previous Story

BP stock slips in premarket as oil dips on Venezuela turmoil — what investors watch next

Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next
Next Story

Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next